Skip To Main Content
Greg Cima on Muck Rack

Greg Cima

Verified
(He/Him)
Illinois
As seen in: 360Dx, GenomeWeb, Genetic Literacy Project, American Veterinary Medical Association [AVMA], Journal of the American Veterinary Medical Association (JAVMA), Pantagraph, Drovers, Precision Medicine Online, Precision Oncology News, Outcome Capital
Covers:  Healthcare, science, business, medical technology
Doesn't Cover: Complementary and alternative medicine
Science and business reporter for 360Dx/GenomeWeb

Get in touch with Greg

Contact Greg, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Greg Cima’s Biography

Read Full Bio →

Experienced reporter who uses strong research, interviewing, and time management skills to tell clear and compelling stories about complex topics including medical diagnostics, biosecurity, disease transmission risks, and corporate financial results

Greg Cima’s Journalist Portfolio

See all →
POC High-Sensitivity Troponin Tests Could Reduce ER Overcrowding. Is That Enough for Adoption?

POC High-Sensitivity Troponin Tests Could Reduce ER Overcrowding. Is That Enough for Adoption?

Several firms are bringing high-sensitivity cardiac troponin testing into the ER, although doctors are not ye…

View article →
Children's Hospitals Brace for Reduced Test Access, Higher Costs Under LDT Final Rule

Children's Hospitals Brace for Reduced Test Access, Higher Costs Under LDT Final Rule

Pathology directors expect that they will be unable to send out or receive samples for new tests when the FDA…

View article →
Rabbit, hare populations recovering from viral disease

Rabbit, hare populations recovering from viral disease

Rabbit and hare populations appear to have largely recovered from a viral disease that caused die-offs in the…

View article →
Finding the spreaders of chronic wasting disease

Finding the spreaders of chronic wasting disease

Research teams are working to improve tests used to find the prions that cause chronic wasting disease, track…

View article →
As Molecular Testing Expands, Labs Find Reimbursement Process Becoming a Herculean Task

As Molecular Testing Expands, Labs Find Reimbursement Process Becoming a Herculean Task

Laboratories and lab consultants said that they have seen in recent years a more adversarial and uncertain re…

View article →
New Sepsis Testing Tools Emerging While Adoption Drags Amid Clinical Utility Concerns

New Sepsis Testing Tools Emerging While Adoption Drags Amid Clinical Utility Concerns

Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the…

View article →

Articles

Arima Genomics Aims to Replace Some FISH-Based Cancer Tests With Hi-C Sequencing Assays Original

|
By Greg Cima Verified
| GenomeWeb Verified
NEW YORK – Backed by promising results from a recent small study, Arima Genomics believes that its Hi-C lymphoma assay can eventually replace fluorescence in situ hybridization (FISH)-based tests to inform treatment decisions. With Arima's focus on developing and commercializing tests using its 3D genomics technology, the company last year bought out its partner on a joint venture on a clinical lab that it is using to commercialize its Hi-C assays.
Open in Who Shared View Duplicates (2) Issue with article?

Diasorin Moves to Expand Test Menu and Shore up Sales as Q3 Revenues Decline

|
By Greg Cima Verified
| 360Dx Verified
This story has been updated to include comments from Diasorin's Q3 earnings call on Wednesday. NEW YORK – With recent regulatory approvals secured and more pending, Diasorin said that it is expanding its immunodiagnostics and molecular diagnostics menus with tests that can help shore up demand and expand its reach into hospitals.
Open in Who Shared View Duplicates (4) Issue with article?

Siemens Healthineers Prepares for Possible Changes by Parent Firm as Q4 Dx Revenues Fall 4 Percent

|
By Greg Cima Verified
| 360Dx Verified
NEW YORK – Siemens Healthineers officials have been in discussions with banks and ratings agencies as its parent company Siemens ponders if it will reduce its stake in the subsidiary to below 50 percent. Jochen Schmitz, Siemens Healthineers CFO, said in a conference call for the company's Q4 earnings on Wednesday that a decoupling from Siemens could involve the termination of existing financing agreements, which would require that Siemens Healthineers repay loans and refinance.
Open in Who Shared Issue with article?
See all 426 licensed articles (427 Total)